Rhabdomyolysis reported for children and adolescents treated with antipsychotic medicines: A case series analysis

Journal of Child and Adolescent Psychopharmacology

Volumn 22, Issue 6, 2012, Pages 440-451

  Star, Kristina ^a,b   Iessa, Noha ^c   Almandil, Noor B ^c   Wilton, Lynda ^c   Curran, Sarah ^d   Ralph Edwards, I ^a   Wong, Ian C K ^c,e  

^a UPPSALA MONITORING CENTRE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; CHLORPROMAZINE; CLOZAPINE; CREATINE KINASE; CYAMEMAZINE; DIAZEPAM; DIPHENHYDRAMINE; FLUVOXAMINE; HALOPERIDOL; LITHIUM; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; SERTINDOLE; TETRABENAZINE; TOPIRAMATE; TRIHEXYPHENIDYL; VALPROATE SEMISODIUM; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE; ZONISAMIDE; ZOTEPINE;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADOLESCENT; ARTICLE; ASPERGER SYNDROME; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BIPOLAR DISORDER; CHILD; CLINICAL FEATURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; HUMAN; HYPOTHERMIA; KIDNEY FAILURE; META ANALYSIS; MYALGIA; MYOGLOBINURIA; MYOSITIS; NEUROLEPTIC MALIGNANT SYNDROME; OBSESSIVE COMPULSIVE DISORDER; OPPOSITIONAL DEFIANT DISORDER; PSYCHOSIS; RASH; RHABDOMYOLYSIS; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VESICULAR RASH; WEAKNESS;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; MALE; RESEARCH DESIGN; RHABDOMYOLYSIS; RISK FACTORS; TIME FACTORS;

EID: 84871223737     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2011.0134     Document Type: Article

References (41)

1. Almandil NB, Liu Y, Murray LM, Besag FMC, Aitchison KJ, Wong ICK: Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: A systematic review and meta-analysis. Paediatr Drugs (in press).
2. Almandil NB, Wong IC: Review on the current use of antipsychotic drugs in children and adolescents. Arch Dis Child Educ Pract Ed 96:192-196, 2011.
3. Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, De Freitas RM: A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54:315-321, 1998. (Pubitemid 28328016)
4. Bégaud B, Evreux JC, Jouglard J, Lagier G: Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France [in French]. Thérapie 40:111-118, 1985.
5. Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT: Secondgeneration antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 14:372-394, 2004. (Pubitemid 39473123)
6. Correll CU, Carlson HE: Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 45:771-791, 2006. DRUGDEX System. Micromedex 2.0. Available at www.thomsonhc. com/micromedex/librarian Accessed November 8, 2012. (Pubitemid 43932904)
7. Elsayed EF, Reilly RF: Rhabdomyolysis: A review, with emphasis on the pediatric population. Pediatr Nephrol 25:7-18, 2010.
8. Gabow PA, Kaehny WD, Kelleher SP: The spectrum of rhabdomyolysis. Medicine (Baltimore) 61:141-152, 1982. (Pubitemid 12073570)
9. Gieteling MJ, Lisman-van Leeuwen Y, van der Wouden JC, Schellevis FG, Berger MY: Childhood nonspecific abdominal pain in family practice: Incidence, associated factors, and management. Ann Fam Med 9:337-343, 2011.
10. Hanft A, Eggleston CF, Bourgeois JA: Neuroleptic malignant syndrome in an adolescent after brief exposure to olanzapine. J Child Adolesc Psychopharmacol 14:481-487, 2004. (Pubitemid 39473136)
11. Hazell L, Shakir SA: Under-reporting of adverse drug reactions: A systematic review. Drug Saf 29:385-396, 2006.
12. Holtmann M, Meyer AE, Pitzer M, Schmidt MH: Risperidoneinduced marked elevation of serum creatine kinase in adolescence. A case report. Pharmacopsychiatry 36:317-318, 2003. (Pubitemid 38085152)
13. Hung CF, Huang TY, Lin PY: Hypothermia and rhabdomyolysis following olanzapine injection in an adolescent with schizophreniform disorder. Gen Hosp Psychiatry 31:376-378, 2009.
14. Jerrell JM, McIntyre RS: Adverse events in children and adolescents treated with antipsychotic medications. Hum Psychopharmacol 23:283-290, 2008. (Pubitemid 351982665)
15. Jones JK: Adverse drug reactions in the community health setting: approaches to recognizing, counseling, and reporting. Fam Community Health 5:58-67, 1982.
16. Karakaya P, Yis U, Kurul SH, Turkmen MA: Rhabdomyolysis associated with olanzapine treatment in a child with autism. Pediatr Emerg Care 26:41-42, 2010.
17. Kelly WN, Arellano FM, Barnes J, Bergman U, Edwards RI, Fernandez AM, Freedman SB, Goldsmith DI, Huang KA, Jones JK, McLeay R, Moore N, Stather RH, Trenque T, Troutman WG, van Puijenbroek E, Williams F, Wise RP: Guidelines for submitting adverse event reports for publication. Drug Saf 30:367-373, 2007. (Pubitemid 46740334)
18. Lindquist M: Vigibase, the WHO Global ICSR Database System: Basic Facts. Drug Inf J 42:409-419, 2008.
19. Maintenance and Support Service Organization (MSSO). (2010). MedDRA-the Medical Dictionary for Regulatory Activities. Available at www.meddramsso.com Accessed November 19, 2010.
20. Mannix R, Tan ML, Wright R, Baskin M: Acute pediatric rhabdomyolysis: Causes and rates of renal failure. Pediatrics 118:2119-2125, 2006. (Pubitemid 46393696)
21. Melli G, Chaudhry V, Cornblath DR: Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore) 84:377-385, 2005. (Pubitemid 41668936)
22. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239-245, 1981. (Pubitemid 12149145)
23. Norén GN, Hopstadius J, Bate A: Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res 2011 [Epub ahead of print].
24. Norén GN, Orre R, Bate A, Edwards IR: Duplicate detection in adverse drug reaction surveillance. Data Min Knowl Discov 14:305-328, 2007. (Pubitemid 46582604)
25. Olfson M, Blanco C, Liu L, Moreno C, Laje G: National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 63:679-685, 2006. (Pubitemid 43848299)
26. Pathak P, West D, Martin BC, Helm ME, Henderson C: Evidencebased use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005. Psychiatr Serv 61:123-129, 2010.
27. Rani FA, Byrne P, Cranswick N, Murray ML, Wong IC: Mortality in children and adolescents prescribed antipsychotic medication: A retrospective cohort study using the UK general practice research database. Drug Saf 34:773-781, 2011.
28. Rani FA, Byrne PJ, Murray ML, Carter P, Wong IC: Paediatric atypical antipsychotic monitoring safety (PAMS) study: pilot study in children and adolescents in secondary-and tertiary-care settings. Drug Saf 32:325-333, 2009.
29. Rani FA, Murray ML, Byrne PJ, Wong IC: Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 121:1002-1009, 2008.
30. Ribeyron S, Guy C, Koenig M, Cathebras P: Olanzapine induced rhabdomyolysis and serum creatine kinase increase [in French]. Rev Méd Interne 30:477-485, 2009.
31. Rosebraugh CJ, Flockhart DA, Yasuda SU, Woosley RL: Olanzapineinduced rhabdomyolysis. Ann Pharmacother 35:1020-1023, 2001.
32. Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, McNamara NK, Delporto-Bedoya D, Anderson R, Hamer RM, Lieberman JA: Double-blind comparison of first-and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: Findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 165:1420-1431, 2008.
33. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA: A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: A double-blind, randomized, 8-week trial. Neuropsychopharmacology 29:133-145, 2004. (Pubitemid 38068023)
34. Strawn JR, Adler CM, Strakowski SM, DelBello MP: Hyperthermia and rhabdomyolysis in an adolescent treated with topiramate and olanzapine. J Child Adolesc Psychopharmacol 18:116-118, 2008. (Pubitemid 351311247)
35. Summary of Product Characteristics (UK). (2012). Olanzapine. Available at www.medicines.org.uk/EMC/searchresults.aspx?term= olanzapine&searchtype = QuickSearch Accessed July 5, 2012.
36. Vandenbroucke JP: Case reports in an evidence-based world. J R Soc Med 92:159-163, 1999. (Pubitemid 29213858)
37. Vandenbroucke JP: In defense of case reports and case series. Ann Intern Med 134:330-334, 2001. (Pubitemid 32163956)
38. Watson WA, Litovitz TL, Klein-Schwartz W, Rodgers GC, Jr., Youniss J, Reid N, Rouse WG, Rembert RS, Borys D: 2003 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 22:335-404, 2004. (Pubitemid 39201291)
39. WHO Collaborating Centre for Drug Statistics Methodology. ATC classification index with DDDs, Oslo, 2008
40. Wu CT, Huang JL, Lin JJ, Hsia SH: Factors associated with nontraumatic rhabdomyolysis and acute renal failure of children in Taiwan population. Pediatr Emerg Care 25:657-660, 2009.
41. Yoshikawa H, Watanabe T, Abe T, Oda Y, Ozawa K: Haloperidolinduced rhabdomyolysis without neuroleptic malignant syndrome in a handicapped child. Brain Dev 22:256-258, 2000. (Pubitemid 30323840)